Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab

Switching of biologic agents in treatment of plaque psoriasis is a common strategy. Only a few studies are available on switching between IL17A-blockers. In a retrospective study, we identified 22 psoriasis patients who, after failing secukinumab as a first IL17A-blocker received ixekizumab with an...

Full description

Saved in:
Bibliographic Details
Published in:Dermatology online journal 2020-01, Vol.26 (1)
Main Authors: Amschler, K, Phillip, S, Mohr, J, Wilsmann-Theis, D, Poortinga, S, Gerdes, S, Mössner, R
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal, Humanized - therapeutic use
Dermatologic Agents - therapeutic use
Dermatology
Drug Resistance
Female
Follow-Up Studies
Humans
Interleukin-17 - antagonists & inhibitors
Male
Middle Aged
Monoclonal antibodies
Psoriasis
Psoriasis - drug therapy
Retrospective Studies
Transdermal medication
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Switching of biologic agents in treatment of plaque psoriasis is a common strategy. Only a few studies are available on switching between IL17A-blockers. In a retrospective study, we identified 22 psoriasis patients who, after failing secukinumab as a first IL17A-blocker received ixekizumab with an observation period of at least 24 weeks. At last observation 10/22 patients had a good response (PASI75 or PASI
ISSN:1087-2108
1087-2108
DOI:10.5070/D3261047182